| Region reporting | African region | 43 (0.51) |
| Region of the Americas | 5,210 (62.37) |
| Southeast Asia region | 52 (0.62) |
| European region | 2,277 (27.26) |
| Eastern Mediterranean region | 35 (0.42) |
| Western Pacific region | 737 (8.82) |
| Reporting year | 1968-1979 | 16 (0.19) |
| 1980-1989 | 103 (1.23) |
| 1990-1999 | 242 (2.90) |
| 2000-2009 | 426 (5.10) |
| 2010-2019 | 4,244 (50.8) |
| 2020-2024 | 3,323 (39.78) |
| Reporter qualification | Health professional | 2,489 (29.79) |
| Non-health professional | 450 (5.39) |
| Sex | Male | 4,083 (48.87) |
| Female | 4,070 (48.72) |
| Unknown | 201 (2.41) |
| Age, years | 0 to 11 | 3,897 (46.65) |
| 12 to 17 | 344 (4.12) |
| 18 to 44 | 1,426 (17.07) |
| 45 to 64 | 987 (11.81) |
| ≥65 | 790 (9.46) |
| Unknown | 910 (10.89) |
| TTO, days | Median days (IQR) | 1 (1-1) |
| Drug class | Anthrax vaccines | 41 (0.49) |
| Cholera vaccines | 1 (0.01) |
| DTaP-IPV-Hib vaccines | 1,789 (21.41) |
| Meningococcal vaccines | 240 (2.87) |
| Pneumococcal vaccines | 619 (7.41) |
| Tuberculosis vaccines | 9 (0.11) |
| Typhoid vaccines | 50 (0.60) |
| Encephalitis vaccines | 51 (0.61) |
| Influenza vaccines | 611 (7.31) |
| Hepatitis A vaccines | 210 (2.51) |
| Hepatitis B vaccines | 389 (4.66) |
| MMR vaccines | 810 (9.70) |
| Rotavirus diarrhea vaccines | 157 (1.88) |
| Zoster vaccines | 407 (4.87) |
| Papillomavirus vaccines | 150 (1.80) |
| COVID-19 mRNA vaccines | 2,340 (28.01) |
| Ad5-vectored COVID-19 vaccines | 248 (2.97) |
| Inactivated whole-virus COVID-19 vaccines | 24 (0.29) |
| Other viral vaccines* | 122 (1.46) |
| Others** | 86 (1.03) |
| Fatal outcomes | Recovered | 4,216 (50.47) |
| Not recovered | 827 (9.90) |
| Fatal | 27 (0.32) |
| Death | 3 (0.04) |
| Unknown | 3,281 (39.27) |
| Single drug suspected | | 8,354 (100.00) |